L3-7582 — Final report
1.
Treatment of antibody-mediated rejection after kidney transplantation - 10 years' experience with apheresis at a single center

The research article presents the treatment and prognosis of antibody-mediated rejection of the transplanted kidney at the Kidney Transplantation Centre of the University Medical Centre Ljubljana and underlines the importance of early detection and treatment of antibody-mediated rejection to improve long-term survival following kidney transplantation.

COBISS.SI-ID: 3277228
2.
Increase in spot urine protein excretion is associated with late kidney graft rejection and predicts rejection phenotype

An increase in spot urine protein excretion before kidney graft dysfunction appears to be associated with graft rejection and predicts antibody-mediated rejection phenotype.

COBISS.SI-ID: 3994284
3.
Clinical biomarkers for kidney allograft rejection

The objective of this review was to provide contemporary data on the diagnostic role of laboratory test-based functional monitoring assays that can be used in everyday clinical practice and use non-invasive samples, such as peripheral blood or spot urine samples that might help distinguish rejection versus non-rejection episodes and between different rejection phenotypes as well as to predict functional recovery after anti-rejection therapy.

COBISS.SI-ID: 2885292
4.
Paricalcitol versus placebo for reduction of proteinuria in kidney transplant recipients

Prospective, randomised, double-blind, placebo-controlled study demonstrated that in kidney transplant recipients addition paricalcitol lowers residual proteinuria, and could be used as an effective approach to lower allograft failure risk.

COBISS.SI-ID: 5134252
5.
Effects of paricalcitol on biomarkers of inflammation and fibrosis in kidney transplant recipients

The results of this prospective, randomised study demonstrated that in kidney transplant recipients, addition of paricalcitol lowers proteinuria, IL-6 and TGF-beta concentrations, which may be beneficial for reducing graft inflammation and fibrosis.

COBISS.SI-ID: 3993516